Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605184 | PMC |
| http://dx.doi.org/10.1016/j.adro.2024.101663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure.
Antiviral Res
December 2024
Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. Electronic address:
Serum HBV-RNA (seRNA) was proposed to be a circulating marker of cccDNA transcriptional activity in hepatocytes. The combination of tenofovir-disoproxil-fumarate (TDF) and pegylated-interferon-alpha-2a (pegIFN) with nucleic-acid polymer (NAP) treatment was associated with a relatively high rate of functional cure (FC) 48 weeks after discontinuation of all therapy. We aim to characterize seRNA kinetics under TDF and pegIFN±NAP combination therapies.
View Article and Find Full Text PDFPredictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.
Hepatol Int
December 2024
Department of Infectious Diseases, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.
Background And Aims: Chronic hepatitis B (CHB) is a major global health concern. This study aims to investigate the factors influencing hepatitis B surface antigen (HBsAg) clearance in CHB patients treated with pegylated interferon α-2b (Peg-IFNα-2b) for 48 weeks and to establish a predictive model.
Methods: This analysis is based on the "OASIS" project, a prospective real-world multicenter study in China.
Safety and efficacy of 48-week pegylated interferon--2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study.
Front Med (Lausanne)
December 2024
Department of Hepatology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi Province, China.
Background: Pegylated interferon- (PEG-IFN-α) therapy could decrease hepatitis B surface antigen (HBsAg) and improve long-term prognosis of hepatitis B virus (HBV) infection. However, studies on safety and efficacy of PEG-IFN- for patients with HBV-related cirrhosis are limited.
Methods: This was a single-center study.
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies.
Gut
December 2024
Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has represented the only therapeutic option, with limited virological response rates and poor tolerability. In 2020, the European Medicines Agency approved bulevirtide (BLV) at 2 mg/day, an entry inhibitor of hepatitis B virus (HBV)/hepatitis delta virus (HDV), which proved to be safe and effective as a monotherapy for up to 144 weeks in clinical trials and real-life studies, including patients with cirrhosis.
View Article and Find Full Text PDFAchieving chronic hepatitis B functional cure: Factors and potential mechanisms.
Virus Res
December 2024
Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China. Electronic address:
Chronic hepatitis B (CHB) is a significant global health issue affecting approximately 254 million individuals worldwide. Achieving the loss of hepatitis B surface antigen (HBsAg), either with or without seroconversion to hepatitis B surface antibody (HBsAb), is regarded as a functional cure and the optimal goal for addressing CHB, and can be achieved through various approaches, including induction with nucleos(t)ide analogues (NAs), induction with pegylated interferon alpha (PegIFNα), and spontaneous clearance of HBsAg. Spontaneous clearance of HBsAg is rare, while NAs can directly inhibit HBV DNA, they are unable to act on covalently closed circular DNA (cccDNA), hence inhibiting HBsAg production or clearing HBsAg is extremely challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!